A possible strategy for overcoming this limitation due to individual variability and poor diagnostic sensitivity could be combining known autoantibody markers with other biomarkers for gastric cancer, such as tumor markers like carcinoembryonic antigen (CEA) [111], CA19-9 [112], and CA72-4 [113] markers related to chronic atrophic gastritis (e.g., parietal cell antibodies, H. pylori antibodies and serum pepsinogens I and II, gastrin [114]), microRNAs [115] or glycosylation signatures [116]. Here, CEACAM5 is linked to chronic atrophic gastritis.